Integer (ITGR) 10-Q 29 Apr 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Apr. 02, 2021	Apr. 23, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Apr. 2, 2021
Document Transition Report	false
Entity File Number	1-16137
Entity Registrant Name	INTEGER HOLDINGS CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	16-1531026
Entity Address, Address Line One	5830 Granite Parkway,
Entity Address, Address Line Two	Suite 1150
Entity Address, City or Town	Plano,
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75024
City Area Code	214
Local Phone Number	618-5243
Title of 12(b) Security	Common Stock, $0.001 par value per share
Trading Symbol	ITGR
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		32,975,085
Entity Central Index Key	0001114483
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 28,402	$ 49,206
Accounts receivable, net of provision for credit losses of $0.2 million, respectively	165,826	156,207
Inventories	153,815	149,323
Refundable income taxes	2,461	2,087
Contract assets	44,686	40,218
Prepaid expenses and other current assets	14,047	15,896
Total current assets	409,237	412,937
Property, plant and equipment, net	248,993	253,964
Goodwill	852,243	859,442
Other intangible assets, net	739,334	757,224
Deferred income taxes	4,381	4,398
Operating lease assets	50,433	45,153
Other long-term assets	38,731	38,739
Total assets	2,343,352	2,371,857
Current liabilities:
Current portion of long-term debt	37,500	37,500
Accounts payable	62,395	51,570
Income taxes payable	3,610	1,847
Operating lease liabilities	7,904	8,431
Accrued expenses and other current liabilities	50,142	56,843
Total current liabilities	161,551	156,191
Long-term debt	649,630	693,758
Deferred income taxes	180,779	182,304
Operating lease liabilities	45,150	37,861
Other long-term liabilities	28,518	30,688
Total liabilities	1,065,628	1,100,802
Commitments and contingencies (Note 10)
Stockholders’ equity:
Common stock, $0.001 par value; 100,000,000 shares authorized; 32,974,702 and 32,908,178 shares issued and outstanding, respectively	33	33
Additional paid-in capital	703,033	700,814
Retained earnings	539,036	517,516
Accumulated other comprehensive income	35,622	52,692
Total stockholders’ equity	1,277,724	1,271,055
Total liabilities and stockholders’ equity	$ 2,343,352	$ 2,371,857

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Apr. 02, 2021	Dec. 31, 2020
Current assets:
Allowance for doubtful accounts	$ 0.2	$ 0.2
Stockholders’ equity:
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	32,974,702	32,908,178
Common stock, shares outstanding (in shares)	32,974,702	32,908,178

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Income Statement [Abstract]
Sales	$ 290,467	$ 328,426
Cost of sales	205,981	231,724
Gross profit	84,486	96,702
Operating expenses:
Selling, general and administrative	35,502	36,457
Research, development and engineering	13,461	13,241
Other operating expenses	915	2,928
Total operating expenses	49,878	52,626
Operating income	34,608	44,076
Interest expense	8,532	10,361
(Gain) loss on equity investments	1,335	(1,925)
Other income, net	(237)	(999)
Income before taxes	24,978	36,639
Provision for income taxes	3,458	5,539
Net income	$ 21,520	$ 31,100
Earnings per share:
Basic (in dollars per share)	$ 0.65	$ 0.95
Diluted (in dollars per share)	$ 0.65	$ 0.94
Weighted average shares outstanding:
Basic (in shares)	32,957	32,807
Diluted (in shares)	33,188	33,117
Comprehensive Income
Net income	$ 21,520	$ 31,100
Other comprehensive loss:
Foreign currency translation loss	(16,364)	(12,032)
Change in fair value of cash flow hedges, net of tax	(706)	(8,629)
Other comprehensive loss, net of tax	(17,070)	(20,661)
Comprehensive income, net of tax	$ 4,450	$ 10,439

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Cash flows from operating activities:
Net income	$ 21,520	$ 31,100
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	20,294	19,494
Debt related charges included in interest expense	1,372	1,023
Stock-based compensation	4,704	1,738
Non-cash (gains) charges related to customer bankruptcy	(24)	628
Non-cash lease expense	2,004	1,930
Non-cash (gain) loss on equity investments	1,335	(1,925)
Contingent consideration fair value adjustment	0	(500)
Other non-cash (gains) losses	69	(585)
Deferred income taxes	(242)	61
Changes in operating assets and liabilities, net of acquisition:
Accounts receivable	(9,373)	(8,165)
Inventories	(5,157)	(4,365)
Prepaid expenses and other assets	(189)	929
Contract assets	(4,677)	(14,279)
Accounts payable	11,434	18,458
Accrued expenses and other liabilities	(7,887)	(18,108)
Income taxes	1,246	4,963
Net cash provided by operating activities	36,429	32,397
Cash flows from investing activities:
Acquisition of property, plant and equipment	(7,660)	(14,925)
Purchase of intangible asset	0	(3,500)
Proceeds from sale of property, plant and equipment	15	52
Acquisitions, net	0	(5,219)
Net cash used in investing activities	(7,645)	(23,592)
Cash flows from financing activities:
Principal payments of long-term debt	(45,375)	(9,375)
Proceeds from senior secured revolving line of credit	0	25,000
Proceeds from the exercise of stock options	116	2,201
Payment of debt issuance costs	(72)	0
Tax withholdings related to net share settlements of restricted stock unit awards	(2,601)	(2,664)
Contingent consideration payments	(1,621)	0
Principal payments on finance leases	(9)	0
Net cash provided by (used in) financing activities	(49,562)	15,162
Effect of foreign currency exchange rates on cash and cash equivalents	(26)	(243)
Net increase (decrease) in cash and cash equivalents	(20,804)	23,724
Cash and cash equivalents, beginning of period	49,206	13,535
Cash and cash equivalents, end of period	$ 28,402	$ 37,259

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - Unaudited - USD ($) $ in Thousands	Total	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Balance, beginning of period at Dec. 31, 2019	$ 1,152,488	$ 701,051	$ (8,809)	$ 440,258	$ 19,988
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		(8,010)
Stock-based compensation		1,738
Treasury shares reissued			7,546
Net income	31,100			31,100
Other comprehensive loss	(20,661)				(20,661)
Balance, ending balance at Apr. 03, 2020	1,164,201	694,779	(1,263)	471,358	(673)
Balance, beginning of period at Dec. 31, 2020	1,271,055	700,847	0	517,516	52,692
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock awards exercised or vested		(2,485)
Stock-based compensation		4,704
Treasury shares reissued			0
Net income	21,520			21,520
Other comprehensive loss	(17,070)
Balance, ending balance at Apr. 02, 2021	$ 1,277,724	$ 703,066	$ 0	$ 539,036	$ 35,622

Basis of Presentation

Basis of Presentation	3 Months Ended
	Apr. 02, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Integer Holdings Corporation (together with its consolidated subsidiaries, “Integer” or the “Company”) is a publicly-traded corporation listed on the New York Stock Exchange under the symbol “ITGR.” Integer is one of the largest medical device outsource manufacturers in the world serving the cardiac, neuromodulation, vascular, orthopedics, advanced surgical and portable medical markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in the energy, military, and environmental markets. The Company’s reportable segments are: (1) Medical and (2) Non-Medical. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The first quarter of 2021 ended on April 2 and consisted of 92 days, and the first quarter of 2020 ended on April 3 and consisted of 94 days. Risks and Uncertainties Beginning in early March 2020, the global spread of the novel coronavirus (“COVID-19”) created significant uncertainty and worldwide economic disruption. Specific impacts to the Company’s business include delayed or reduced customer orders and sales, restrictions on its associates’ ability to travel or work, delays in shipments to and from certain countries, and disruptions in its supply chain. The extent to which COVID-19 impacts the Company’s operations will depend on future developments, which are highly uncertain and difficult to predict, including, among others, the duration of the outbreak, the effectiveness and utilization of vaccines for COVID-19 and its variants, new information that may emerge concerning the severity of COVID-19 and the actions, especially those taken by governmental authorities to contain the pandemic or treat its impact. As pandemic-related events continue to evolve, additional impacts may arise that the Company is not aware of currently. Any prolonged material disruption of the Company’s associates, suppliers, manufacturing, or customers could materially impact its consolidated financial position, results of operations or cash flows. Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued by the Financial Accounting Standards Board ("FASB"). The Company evaluated all recent accounting pronouncements issued, including those that are currently effective, and determined that the adoption of these pronouncements would not have a material effect on the financial position, results of operations or cash flows of the Company. There have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, that are of significance, or potential significance, to the Company.

Business Acquisition

Business Acquisition	3 Months Ended
	Apr. 02, 2021
Business Combinations [Abstract]
BUSINESS ACQUISITION	BUSINESS ACQUISITION On February 19, 2020, the Company acquired certain assets and liabilities of InoMec Ltd. (“InoMec”), a privately-held company based in Israel that specializes in the research, development and manufacturing of medical devices, including minimally invasive tools, delivery systems, tubing and catheters, surgery tools, drug-device combination, laser combined devices, and tooling and production. The acquisition enables the Company to create a research and development center in Israel, closer to the customer base in the region. The fair value of the consideration transferred was $7.0 million, which included an initial cash payment of $5.3 million and $1.7 million in estimated fair value of contingent consideration. The contingent consideration represents the estimated fair value of the Company’s obligation, under the asset purchase agreement, to make additional payments of up to $3.5 million over the four years following the acquisition based on specified conditions being met. Based on the final purchase price allocation, the assets acquired principally comprise $2.0 million of intangible assets, $4.8 million of goodwill, $0.3 million of acquired property, plant and equipment, and a net liability for other working capital items of $0.1 million. Intangible assets included developed technology, customer relationships and non-compete provisions, which are being amortized over a weighted average period of 5.9 years from the date of acquisition. The amount allocated to goodwill for this acquisition is deductible for income tax purposes. The fair value of the contingent consideration was estimated using the Monte Carlo valuation approach. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. For segment reporting purposes, the results of operations and assets from this acquisition have been included in the Company’s Medical segment since the acquisition date. Sales related to InoMec were $0.8 million and $0.4 million, respectively, for the three months ended April 2, 2021 and April 3, 2020. Earnings related to the operations consisting of the assets and liabilities acquired from InoMec for the three months ended April 2, 2021 and April 3, 2020 were not material. During the three months ended on April 3, 2020, direct costs of this acquisition of $0.7 million were expensed as incurred and included in Other operating expenses in the Condensed Consolidated Statements of Operations and Comprehensive Income. Pro forma financial information has not been presented for this acquisition as the net effects were not significant or material to the Company’s results of operations or financial position.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Apr. 02, 2021
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION The following is supplemental information relating to the Condensed Consolidated Statements of Cash Flows (in thousands): Three Months Ended April 2, April 3, Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 2,981 $ 4,481 Purchase of intangible asset included in accrued expenses — 1,000 Supplemental lease disclosures: Operating lease assets obtained in exchange for new or remeasured operating 7,414 7,427

Inventories

Inventories	3 Months Ended
	Apr. 02, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories comprise the following (in thousands): April 2, December 31, Raw materials $ 70,552 $ 72,477 Work-in-process 64,320 58,806 Finished goods 18,943 18,040 Total $ 153,815 $ 149,323

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets, Net	3 Months Ended
	Apr. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS, NET	GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The changes in the carrying amount of goodwill by reportable segment for the three months ended April 2, 2021 were as follows (in thousands): Medical Non- Medical Total December 31, 2020 $ 842,442 $ 17,000 $ 859,442 Foreign currency translation (7,199) — (7,199) April 2, 2021 $ 835,243 $ 17,000 $ 852,243 Intangible Assets Intangible assets comprise the following (in thousands): Gross Accumulated Net April 2, 2021 Definite-lived: Purchased technology and patents $ 255,606 $ (155,278) $ 100,328 Customer lists 716,081 (167,620) 548,461 Other 4,120 (3,863) 257 Total amortizing intangible assets $ 975,807 $ (326,761) $ 649,046 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288 Aggregate intangible asset amortization expense comprises the following (in thousands): Three Months Ended April 2, April 3, Cost of sales $ 3,268 $ 3,269 Selling, general and administrative expenses 7,182 7,175 Total intangible asset amortization expense $ 10,450 $ 10,444 Estimated future intangible asset amortization expense based on the carrying value as of April 2, 2021 is as follows (in thousands): Remainder of 2021 2022 2023 2024 2025 After 2025 Amortization Expense $ 30,835 40,170 38,751 37,798 36,483 465,009

Debt

Debt	3 Months Ended
	Apr. 02, 2021
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt comprises the following (in thousands): April 2, December 31, Senior secured term loan A $ 220,312 $ 229,687 Senior secured term loan B 472,286 508,286 Unamortized discount on term loan B and debt issuance costs (5,468) (6,715) Total debt 687,130 731,258 Current portion of long-term debt (37,500) (37,500) Total long-term debt $ 649,630 $ 693,758 The Company has senior secured credit facilities (the “Senior Secured Credit Facilities”) as of April 2, 2021, consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a term loan A facility (the “TLA Facility”), and (iii) a term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB Facility was issued at a 1% discount. Revolving Credit Facility The Revolving Credit Facility matures on October 27, 2022. The Revolving Credit Facility includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25%, depending on the Company’s Total Net Leverage Ratio (as defined in the Senior Secured Credit Facilities agreement). As of April 2, 2021, the commitment fee on the unused portion of the Revolving Credit Facility was 0.25%. Interest rates on the Revolving Credit Facility, as well as the TLA Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.50% and 2.00%, based on the Company’s Total Net Leverage Ratio, or (ii) the applicable London Interbank Offered Rate (“LIBOR”) plus the applicable margin, which will range between 1.50% and 3.00%, based on the Company’s Total Net Leverage Ratio. The Company also pays certain of its lenders a deferred amendment fee, payable in installments of 0.03125% of the outstanding Revolving Credit Facility and TLA Facility each quarter through maturity when the Company’s total net leverage ratio equals or exceeds 3.00 to 1.00. As of April 2, 2021, the Company had no outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $193.3 million after giving effect to $6.7 million of outstanding standby letters of credit. Term Loan Facilities The TLA Facility and TLB Facility mature on October 27, 2022. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 1.50% or (ii) the applicable LIBOR rate plus 2.50%, with LIBOR subject to a 1.00% floor. As of April 2, 2021, the interest rates on the TLA Facility and TLB Facility were 2.36% and 3.50%, respectively. Covenants The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 4.75:1.00, subject to a step down to 4.50 to 1.00 for the third fiscal quarter of 2021, and reverting to and remaining at 4.00 to 1.00 beginning with the fourth quarter of 2021 through maturity, and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the Senior Secured Credit Facilities) to interest expense of not less than 3.00:1.00. The TLB Facility does not contain any financial maintenance covenants. As of April 2, 2021, the Company was in compliance with these financial covenants. Contractual maturities under the Senior Secured Credit Facilities for the remainder of 2021 and through maturity, excluding any discounts or premiums, as of April 2, 2021 are as follows (in thousands): 2021 2022 Future minimum principal payments $ 28,125 664,473 During the three months ended April 2, 2021, the Company prepaid $36.0 million of its TLB Facility and recognized a loss from extinguishment of debt of $0.3 million. The loss from extinguishment of debt represents the portion of the unamortized discount and debt issuance costs related to the portion of the TLB Facility that was prepaid and is included in Interest expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Apr. 02, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION The Company maintains certain stock-based compensation plans that were approved by the Company’s stockholders and are administered by the Board of Directors or the Compensation and Organization Committee of the Board. The stock-based compensation plans provide for the granting of stock options, restricted stock awards, restricted stock units (“RSUs”), stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended April 2, April 3, Stock options $ — $ 13 RSUs 4,704 1,725 Total stock-based compensation expense $ 4,704 $ 1,738 Cost of sales $ 1,114 $ 454 Selling, general and administrative 3,355 1,136 Research, development and engineering 235 148 Total stock-based compensation expense $ 4,704 $ 1,738 Stock Options The following table summarizes the Company’s stock option activity for the three month period ended April 2, 2021: Number of Weighted Weighted Aggregate Outstanding at December 31, 2020 281,873 $ 36.05 Exercised (4,229) 27.32 Outstanding and exercisable at April 2, 2021 277,644 $ 36.18 4.5 $ 15.4 Restricted Stock Units During the three months ended April 2, 2021, the Company awarded grants of either time-based RSUs or a mix of time-based RSUs and performance-based RSUs (“PRSUs”) to certain members of its Board of Directors and management. Newly appointed members to the Board of Directors received a pro-rated portion of the their annual equity retainer in the form of time-based RSUs that vest in accordance with the regularly scheduled vesting schedule applicable to existing members of the Board of Directors. All other time-based RSUs granted during three months ended April 2, 2021 vest ratably, subject to the recipient’s continuous service to the Company over a period of three years from the grant date. For the Company’s PRSUs, in addition to service conditions, the ultimate number of shares to be earned depends on the achievement of market-based conditions. The market-based conditions are based on the Company’s achievement of a relative total shareholder return (“TSR”) performance requirement, on a percentile basis, compared to a defined group of peer companies over three year performance periods. The Company uses a Monte Carlo simulation model to determine the grant-date fair value of awards with TSR-based performance conditions. The grant-date fair value of all other RSUs is equal to the closing market price of Integer common stock on the date of grant. (7.) STOCK-BASED COMPENSATION (Continued) The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: Three Months Ended April 2, April 3, Weighted average fair value $ 85.16 $ 107.42 Risk-free interest rate 0.19 % 1.53 % Expected volatility 41 % 30 % Expected life (in years) 3.0 2.9 Expected dividend yield — % — % The valuation of the TSR portion of the PRSUs granted during 2021 and 2020 also reflects a weighted average illiquidity discount of 8.19% and 8.00%, respectively, related to the six-month period that recipients are restricted from selling, transferring, pledging or assigning the underlying shares, in the event of vesting. The following table summarizes time-vested RSU activity for the three month period ended April 2, 2021: Time-Vested Weighted Nonvested at December 31, 2020 207,923 $ 75.38 Granted 146,247 79.09 Vested (59,143) 63.94 Forfeited (2,327) 80.24 Nonvested at April 2, 2021 292,700 $ 79.51 The following table summarizes PRSU activity for the three month period ended April 2, 2021: Performance- Weighted Nonvested at December 31, 2020 219,391 $ 72.33 Granted 92,345 85.16 Vested (38,882) 37.75 Forfeited (65,941) 49.00 Nonvested at April 2, 2021 206,913 $ 91.98

Other Operating Expenses

Other Operating Expenses	3 Months Ended
	Apr. 02, 2021
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES	OTHER OPERATING EXPENSES Other operating expenses comprise the following (in thousands): Three Months Ended April 2, April 3, Operational excellence initiatives $ 654 $ 974 Strategic reorganization and alignment — 548 Manufacturing alignment to support growth — 128 Acquisition and integration 84 356 Other general expenses 177 922 Total other operating expenses $ 915 $ 2,928 Operational excellence initiatives The Company’s operational excellence initiatives mainly consist of costs associated with executing on its sales force, manufacturing, business process and performance excellence operational strategic imperatives. These projects focus on changing the Company’s organizational structure to match product line growth strategies and customer needs, transitioning its manufacturing process into a competitive advantage and standardizing and optimizing its business processes. 2021 Initiatives - Costs related to the Company’s 2021 initiatives are primarily recorded within the Medical segment and mainly include termination benefits. The Company estimates that it will incur aggregate pre-tax charges in connection with the 2021 realignment plan of between approximately $1 million to $2 million, the majority of which are expected to be cash expenditures. As of April 2, 2021, total restructuring and related charges incurred since inception was $0.4 million. These actions are expected to be substantially completed by the end of 2021. 2020 Initiatives - Costs related to the Company’s 2020 initiatives are primarily recorded within the Medical segment and mainly include termination benefits. As of April 2, 2021, total restructuring and related charges incurred since inception was $3.0 million. These actions were substantially complete at the end of 2020. Strategic reorganization and alignment These initiatives primarily included aligning resources with the Company’s strategic direction, improving profitability to invest in accelerated growth and the expansion of a facility. These actions began in 2017 and were completed during the second quarter of 2020. The Company recorded, primarily within the Medical segment, $23.0 million of restructuring and related charges since inception. Manufacturing alignment to support growth These initiatives were designed to reduce costs, increase manufacturing capacity to accommodate growth and improve operating efficiencies by relocating certain manufacturing operations and expanding certain facilities. These actions began in 2017 and were completed during the fourth quarter of 2020. The Company recorded, primarily within the Medical segment, $5.8 million of restructuring and related charges since inception. The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheets, related to the initiatives described above (in thousands): Operational December 31, 2020 $ 291 Charges incurred, net of reversals 654 Cash payments (306) April 2, 2021 $ 639 (8.) OTHER OPERATING EXPENSES (Continued) Acquisition and integration Acquisition and integration costs primarily consist of professional fees and other costs related to business acquisitions. During the three months ended April 2, 2021 and April 3, 2020, acquisition and integration costs included $0.1 million and $0.9 million, respectively, of expenses related to the acquisition of certain assets and liabilities of InoMec and US BioDesign, LLC (“USB”), which was acquired in October 2019. Acquisition and integration costs for the three months ended April 3, 2020, also includes a $0.5 million adjustment to reduce the fair value of acquisition-related contingent consideration liability associated with the Company’s acquisition of USB. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information related to the fair value measurement of the contingent consideration. Other general expenses During the three months ended April 2, 2021 and April 3, 2020, the Company recorded expenses related to other initiatives not described above, which relate primarily to integration and operational initiatives to reduce future costs and improve efficiencies. The 2021 and 2020 amounts primarily include data archiving expenses, information technology systems conversion expenses, and expenses related to the restructuring of certain legal entities of the Company.

Income Taxes

Income Taxes	3 Months Ended
	Apr. 02, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. In addition, the Company continues to explore tax planning opportunities that may have a material impact on its effective tax rate. The Company’s effective tax rate for the first quarter of 2021 was 13.8% on $25.0 million of income before taxes compared to 15.1% on $36.6 million of income before taxes for the same period in 2020. The difference between the Company’s effective tax rates and the U.S. federal statutory income tax rate of 21% for the first quarter of 2021 and 2020 is due principally to the net impact of the Company’s earnings outside the U.S., which are generally taxed at rates that differ from the U.S federal rate, the Global Intangible Low-Taxed Income (“GILTI”) tax, the availability of tax credits, and certain discrete tax benefits. For the first quarter of 2021 and 2020, the Company recorded discrete tax benefits of $0.6 million and $1.0 million, respectively. The discrete tax benefits for both periods are predominately related to excess tax benefits recognized upon vesting of RSUs or exercise of stock options during those quarters. As of April 2, 2021 and December 31, 2020, the Company had unrecognized tax benefits of approximately $5.5 million. It is reasonably possible that a reduction of up to $3.4 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. As of April 2, 2021 and December 31, 2020, approximately $5.5 million of the unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized. In response to the COVID-19 pandemic, many governments have enacted or are contemplating measures to provide aid and economic stimulus. These measures may include deferring the due dates of tax payments or other changes to their income and non-income-based tax laws. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which was enacted on March 27, 2020 in the U.S., includes measures to assist companies, including temporary changes to income and non-income- based tax laws. The CARES Act provides for deferred payment of the employer portion of social security taxes through the end of 2020, with 50% of the deferred amount due January 3, 2022 and the remaining 50% due January 3, 2023. As of April 2, 2021 and December 31, 2020, the Company had deferred a total of $9.7 million of payroll taxes. The deferred payroll taxes are included within Accrued expenses and other current liabilities and Other long-term liabilities on the Condensed Consolidated Balance Sheets.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Apr. 02, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Contingent Consideration Arrangements The Company records contingent consideration liabilities related to the earn-out provisions for certain acquisitions. See Note 13 “Financial Instruments and Fair Value Measurements” for additional information. Litigation The Company is subject to litigation arising from time to time in the ordinary course of its business. The Company does not expect that the ultimate resolution of any pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future. Product Warranties The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The product warranty liability is presented within Accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheets. The change in product warranty liability comprised the following (in thousands): December 31, 2020 $ 163 Additions to warranty reserve, net of reversals 15 Adjustments to pre-existing warranties (63) April 2, 2021 $ 115

Earnings Per Share (EPS)

Earnings Per Share (EPS)	3 Months Ended
	Apr. 02, 2021
Earnings Per Share [Abstract]
EARNINGS PER SHARE (EPS)	EARNINGS PER SHARE (“EPS”) The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts): Three Months Ended April 2, April 3, Numerator for basic and diluted EPS: Net income $ 21,520 $ 31,100 Denominator for basic and diluted EPS: Weighted average shares outstanding - Basic 32,957 32,807 Dilutive effect of share-based awards 231 310 Weighted average shares outstanding - Diluted 33,188 33,117 Basic EPS $ 0.65 $ 0.95 Diluted EPS $ 0.65 $ 0.94 The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): Three Months Ended April 2, April 3, Time-vested RSUs 10 101 PRSUs 64 24

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Apr. 02, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY The following is a summary of the number of shares of common stock issued, treasury stock and common stock outstanding for the three month periods ended April 2, 2021 and April 3, 2020: Issued Treasury Stock Outstanding Shares outstanding at December 31, 2020 32,908,178 — 32,908,178 Stock options exercised 4,229 — 4,229 Vesting of RSUs, net of shares withheld to cover taxes 62,295 — 62,295 Shares outstanding at April 2, 2021 32,974,702 — 32,974,702 Shares outstanding at December 31, 2019 32,847,017 (146,546) 32,700,471 Stock options exercised — 58,658 58,658 Vesting of RSUs, net of shares withheld to cover taxes — 66,876 66,876 Shares outstanding at April 3, 2020 32,847,017 (21,012) 32,826,005 Accumulated Other Comprehensive Income (Loss) (“AOCI”) comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax December 31, 2020 $ (1,095) $ (4,956) $ 57,546 $ 51,495 $ 1,197 $ 52,692 Unrealized loss on cash flow hedges — (1,269) — (1,269) 266 (1,003) Realized gain on foreign currency hedges — (659) — (659) 139 (520) Realized loss on interest rate swap hedges — 1,034 — 1,034 (217) 817 Foreign currency translation loss — — (16,364) (16,364) — (16,364) April 2, 2021 $ (1,095) $ (5,850) $ 41,182 $ 34,237 $ 1,385 $ 35,622 December 31, 2019 $ (912) $ (2,358) $ 22,639 $ 19,369 $ 619 $ 19,988 Unrealized loss on cash flow hedges — (11,474) — (11,474) 2,410 (9,064) Realized gain on foreign currency hedges — (197) — (197) 41 (156) Realized loss on interest rate swap hedges — 748 — 748 (157) 591 Foreign currency translation loss — — (12,032) (12,032) — (12,032) April 3, 2020 $ (912) $ (13,281) $ 10,607 $ (3,586) $ 2,913 $ (673)

Financial Instruments and Fair

Financial Instruments and Fair Value Measurements	3 Months Ended
	Apr. 02, 2021
Fair Value Disclosures [Abstract]
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS	FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments and contingent consideration. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. The Company is exposed to global market risks, including the effect of changes in interest rates and foreign currency exchange rates, and uses derivatives to manage these exposures that occur in the normal course of business. The Company does not hold or issue derivatives for trading or speculative purposes. All derivatives are recorded at fair value on the Condensed Consolidated Balance Sheets. The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant April 2, 2021 Assets: Foreign currency contracts $ 28 $ — $ 28 $ — Liabilities: Foreign currency contracts 152 — 152 — Liabilities: Interest rate swap 5,726 — 5,726 — Liabilities: Contingent consideration 2,281 — — 2,281 December 31, 2020 Assets: Foreign currency contracts $ 2,070 $ — $ 2,070 $ — Liabilities: Interest rate swap 7,026 — 7,026 — Liabilities: Contingent consideration 3,900 — — 3,900 Interest Rate Swaps The Company periodically enters into interest rate swap agreements in order to reduce the cash flow risk caused by interest rate changes on its outstanding floating rate borrowings. Under these swap agreements, the Company pays a fixed rate of interest and receives a floating rate equal to one-month LIBOR. The variable rate received from the swap agreements and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The Company has designated these swap agreements as cash flow hedges based on concluding the hedged forecasted transaction is probable of occurring within the period the cash flow hedge is anticipated to affect earnings. Information regarding the Company’s outstanding interest rate swap designated as cash flow hedges as of April 2, 2021 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 150,000 Jun 2020 Jun 2023 2.1785 % 0.1091 % $ (5,726) Other long-term liabilities Information regarding the Company’s outstanding interest rate swap designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2020 Jun 2023 2.1785 % 0.1480 % $ (7,026) Other long-term liabilities (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Foreign Currency Contracts The Company periodically enters into foreign currency forward contracts to hedge its exposure to foreign currency exchange rate fluctuations in its international operations. The Company has designated these foreign currency forward contracts as cash flow hedges. Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of April 2, 2021 is as follows (dollars in thousands): Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 1,553 Apr 2021 Aug 2021 0.0232 UYU Peso $ 30 Prepaid expenses and other current assets 3,270 Apr 2021 Nov 2021 0.0227 UYU Peso 10 Prepaid expenses and other current assets 2,048 Jul 2021 Dec 2021 0.0228 UYU Peso (12) Prepaid expenses and other current assets 8,973 Apr 2021 Sep 2021 1.1949 Euro (133) Accrued expenses and other current liabilities 6,101 Apr 2021 Sep 2021 0.0454 MXN Peso 480 Accrued expenses and other current liabilities 7,269 Apr 2021 Dec 2021 0.0485 MXN Peso (1) Accrued expenses and other current liabilities 10,985 Apr 2021 Dec 2021 1.2206 Euro (362) Accrued expenses and other current liabilities 9,069 Apr 2021 Dec 2021 0.0490 MXN Peso (136) Accrued expenses and other current liabilities Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 16,132 Nov 2020 Sep 2021 1.1949 Euro $ 399 Prepaid expenses and other current assets 10,224 Jan 2021 Sep 2021 0.0454 MXN Peso 922 Prepaid expenses and other current assets 2,656 Jan 2021 Mar 2021 0.0443 MXN Peso 341 Prepaid expenses and other current assets 7,269 Apr 2021 Dec 2021 0.0485 MXN Peso 77 Prepaid expenses and other current assets 3,252 Jan 2021 Aug 2021 0.0232 UYU Peso 165 Prepaid expenses and other current assets 3,966 Jan 2021 Nov 2021 0.0227 UYU Peso 166 Prepaid expenses and other current assets Derivative Instruments with Hedge Accounting Designation The following tables present the effect of cash flow hedge derivative instruments on other comprehensive income (loss) (“OCI”), AOCI and the Company’s Condensed Consolidated Statements of Operations for the three months ended April 2, 2021 and April 3, 2020 (in thousands): Three Months Ended April 2, 2021 April 3, 2020 Total Amount of Gain (Loss) on Cash Flow Hedge Activity Total Amount of Gain (Loss) on Cash Flow Hedge Activity Sales $ 290,467 $ 8 $ 328,426 $ (128) Cost of sales 205,981 624 231,724 325 Operating expenses 49,878 27 52,626 — Interest expense 8,532 (1,034) 10,361 (748) (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Unrealized Gain (Loss) Recognized in OCI Realized Gain (Loss) Reclassified from AOCI Three months ended, Location in Statements of Operations and Comprehensive Income Three months ended, April 2, April 3, April 2, April 3, Interest rate swap $ 266 $ (6,387) Interest expense $ (1,034) $ (748) Foreign exchange forwards (886) (274) Sales 8 (128) Foreign exchange forwards (559) (4,813) Cost of sales 624 325 Foreign exchange forwards (90) — Operating expenses 27 — The Company expects to reclassify net losses totaling $3.2 million related to its cash flow hedges from AOCI into earnings during the next twelve months. Contingent Consideration The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the three months ended April 2, 2021 and April 3, 2020 (in thousands): Three Months Ended April 2, April 3, Fair value measurement at beginning of period $ 3,900 $ 4,200 Amount recorded for acquisitions — 2,700 Fair value measurement adjustment — (500) Payments (1) (1,621) — Foreign currency translation 2 — Fair value measurement at end of period $ 2,281 $ 6,400 __________ (1) Consists of payments associated with the Company’s acquisitions of InoMec and USB, resulting from achievement of revenue-based goals for the period from March 1, 2020 to February 28, 2021 for InoMec and January 1, 2020 to December 31, 2020 for USB. On February 19, 2020, the Company acquired certain assets and liabilities of InoMec. See Note 2 “Business Acquisition” for additional information about the InoMec acquisition. On October 7, 2019, the Company acquired certain assets and liabilities of USB, a privately-held developer and manufacturer of complex braided biomedical structures for disposable and implantable medical devices. The contingent consideration at April 2, 2021 is the estimated fair value of the Company’s obligations, under the asset purchase agreements for InoMec and USB, to make additional payments if certain revenue goals are met. As of April 2, 2021, the current portion of contingent consideration liabilities is $1.0 million and included in Accrued expenses and other current liabilities, and the non-current portion is $1.3 million and included in Other long-term liabilities on the Condensed Consolidated Balance Sheets. As of December 31, 2020, the current portion of contingent consideration liabilities was $1.7 million and included in Accrued expenses and other current liabilities, and the non-current portion was $2.2 million and included in Other long-term liabilities on the Condensed Consolidated Balance Sheets. (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration: April 2, 2021 Contingency Type Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 6,750 $ 2,281 Monte Carlo Revenue volatility 35.0 % Discount rate 4.0 % Projected year(s) of payment 2022-2024 December 31, 2020 Contingency Type Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 9,000 $ 3,900 Monte Carlo Revenue volatility 35.0 % Discount rate 4.0 % Projected year(s) of payment 2021-2024 During the first quarter of 2020, the Company acquired a set of similar identifiable intangible assets relating to a license to use technology within its Non-Medical segment. At the date of acquisition, the Company estimated the original fair value of the contingent consideration to be $1.0 million, which was paid during 2020 upon achievement of the applicable milestones. Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Borrowings under the Company’s Revolving Credit Facility, TLA Facility and TLB Facility accrue interest at a floating rate tied to a standard short-term borrowing index, selected at the Company’s option, plus an applicable margin. The carrying amount of this floating rate debt approximates fair value based upon the respective interest rates adjusting with market rate adjustments. Equity Investments The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Condensed Consolidated Balance Sheets. Non-marketable equity securities are equity securities without readily determinable fair value. The Company has elected the practicability exception to use an alternative approach that measures the securities at cost minus impairment, if any, plus or minus changes resulting from qualifying observable price changes. If an impairment is recognized on the Company’s non-marketable equity securities during the period, these assets are classified as Level 3 within the fair value hierarchy based on the nature of the fair value inputs. Equity investments comprise the following (in thousands): April 2, December 31, Equity method investment $ 20,135 $ 21,470 Non-marketable equity securities 5,723 5,723 Total equity investments $ 25,858 $ 27,193 (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) The components of (Gain) loss on equity investments for each period were as follows (in thousands): Three Months Ended April 2, April 3, Equity method investment (gain) loss $ 1,335 $ (1,925) The Company’s equity method investment is in a venture capital fund focused on investing in life sciences companies. As of April 2, 2021, the Company owned 6.6% of this fund.

Segment Information

Segment Information	3 Months Ended
	Apr. 02, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION The Company organizes its business into two reportable segments: (1) Medical and (2) Non-Medical. This segment structure reflects the financial information and reports used by the Company’s management, specifically its Chief Operating Decision Maker, to make decisions regarding the Company’s business, including resource allocations and performance assessments. This segment structure reflects the Company’s current operating focus in compliance with ASC 280, Segment Reporting . For purposes of segment reporting, intercompany sales between segments are not material. The following table presents sales by product line (in thousands). Three Months Ended April 2, April 3, Segment sales by product line: Medical Cardio & Vascular $ 149,165 $ 179,205 Cardiac & Neuromodulation 108,408 107,820 Advanced Surgical, Orthopedics & Portable Medical 25,392 31,237 Total Medical 282,965 318,262 Non-Medical 7,502 10,164 Total sales $ 290,467 $ 328,426 The following table presents income for the Company’s reportable segments (in thousands). Three Months Ended April 2, April 3, Segment income: Medical $ 55,525 $ 65,216 Non-Medical 2 1,213 Total segment income 55,527 66,429 Unallocated operating expenses (20,919) (22,353) Operating income 34,608 44,076 Unallocated expenses, net (9,630) (7,437) Income before taxes $ 24,978 $ 36,639

Revenue From Contracts With Cus

Revenue From Contracts With Customers	3 Months Ended
	Apr. 02, 2021
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregated Revenue In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of its products and customer relationships and provides meaningful disaggregation of each business segment’s results of operations. For a summary by disaggregated product line sales for each segment, refer to Note 14, “Segment Information.” Revenue recognized from products and services transferred to customers over time represented 35% and 30%, respectively, of total revenue for the three months ended April 2, 2021 and April 3, 2020. All revenue recognized from products and services transferred to customers over time during the periods presented was within the Medical segment. The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues. Three Months Ended April 2, 2021 April 3, 2020 Customer Medical Non-Medical Medical Non-Medical Customer A 22% * 20% * Customer B 13% * 18% * Customer C 17% * 16% * Customer D * 26% * 19% All other customers 48% 74% 46% 81% __________ * Less than 10% of segment’s total revenues for the period. The following tables present revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped. Three Months Ended April 2, 2021 April 3, 2020 Ship to Location Medical Non-Medical Medical Non-Medical United States 53% 69% 55% 44% Puerto Rico * * 12% * United Kingdom * 10% * 15% Singapore * * * 14% Canada * 11% * 12% All other countries 47% 10% 33% 15% __________ * Less than 10% of segment’s total revenues for the period. Contract Balances The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): April 2, December 31, Contract assets $ 44,686 $ 40,218 Contract liabilities 2,379 2,498 Contract assets at April 2, 2021, increased $4.5 million from December 31, 2020, due to a contract modification to add existing products and extend the contractual term. During the three months ended April 2, 2021, the Company recognized $0.9 million of revenue that was included in the contract liability balance as of December 31, 2020. During the three months ended April 3, 2020, the Company recognized $0.1 million of revenue that was included in the contract liability balance as of December 31, 2019.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Apr. 02, 2021
Accounting Policies [Abstract]
Interim Basis of Accounting	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented. Intercompany transactions and balances have been fully eliminated in consolidation.
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company considers the applicability and impact of all Accounting Standard Updates (“ASU”) issued by the Financial Accounting Standards Board ("FASB"). The Company evaluated all recent accounting pronouncements issued, including those that are currently effective, and determined that the adoption of these pronouncements would not have a material effect on the financial position, results of operations or cash flows of the Company. There have been no new or material changes to the significant accounting policies discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, that are of significance, or potential significance, to the Company.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix and amount of pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. In addition, the Company continues to explore tax planning opportunities that may have a material impact on its effective tax rate.
Cost And Equity Method Investments	The Company holds long-term, strategic investments in companies to promote business and strategic objectives. These investments are included in Other long-term assets on the Condensed Consolidated Balance Sheets. Non-marketable equity securities

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Apr. 02, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	The following is supplemental information relating to the Condensed Consolidated Statements of Cash Flows (in thousands): Three Months Ended April 2, April 3, Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 2,981 $ 4,481 Purchase of intangible asset included in accrued expenses — 1,000 Supplemental lease disclosures: Operating lease assets obtained in exchange for new or remeasured operating 7,414 7,427

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Apr. 02, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories comprise the following (in thousands): April 2, December 31, Raw materials $ 70,552 $ 72,477 Work-in-process 64,320 58,806 Finished goods 18,943 18,040 Total $ 153,815 $ 149,323

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets, Net (Tables)	3 Months Ended
	Apr. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by reportable segment for the three months ended April 2, 2021 were as follows (in thousands): Medical Non- Medical Total December 31, 2020 $ 842,442 $ 17,000 $ 859,442 Foreign currency translation (7,199) — (7,199) April 2, 2021 $ 835,243 $ 17,000 $ 852,243
Schedule of Finite-Lived Intangible Assets, Major Class	Intangible assets comprise the following (in thousands): Gross Accumulated Net April 2, 2021 Definite-lived: Purchased technology and patents $ 255,606 $ (155,278) $ 100,328 Customer lists 716,081 (167,620) 548,461 Other 4,120 (3,863) 257 Total amortizing intangible assets $ 975,807 $ (326,761) $ 649,046 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Indefinite-Lived Intangible Assets	Intangible assets comprise the following (in thousands): Gross Accumulated Net April 2, 2021 Definite-lived: Purchased technology and patents $ 255,606 $ (155,278) $ 100,328 Customer lists 716,081 (167,620) 548,461 Other 4,120 (3,863) 257 Total amortizing intangible assets $ 975,807 $ (326,761) $ 649,046 Indefinite-lived: Trademarks and tradenames $ 90,288 December 31, 2020 Definite-lived: Purchased technology and patents $ 257,453 $ (152,798) $ 104,655 Customer lists 723,791 (161,856) 561,935 Other 4,142 (3,796) 346 Total amortizing intangible assets $ 985,386 $ (318,450) $ 666,936 Indefinite-lived: Trademarks and tradenames $ 90,288
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense comprises the following (in thousands): Three Months Ended April 2, April 3, Cost of sales $ 3,268 $ 3,269 Selling, general and administrative expenses 7,182 7,175 Total intangible asset amortization expense $ 10,450 $ 10,444
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based on the carrying value as of April 2, 2021 is as follows (in thousands): Remainder of 2021 2022 2023 2024 2025 After 2025 Amortization Expense $ 30,835 40,170 38,751 37,798 36,483 465,009

Debt (Tables)

Debt (Tables)	3 Months Ended
	Apr. 02, 2021
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt comprises the following (in thousands): April 2, December 31, Senior secured term loan A $ 220,312 $ 229,687 Senior secured term loan B 472,286 508,286 Unamortized discount on term loan B and debt issuance costs (5,468) (6,715) Total debt 687,130 731,258 Current portion of long-term debt (37,500) (37,500) Total long-term debt $ 649,630 $ 693,758
Schedule of Maturities of Long-term Debt	Contractual maturities under the Senior Secured Credit Facilities for the remainder of 2021 and through maturity, excluding any discounts or premiums, as of April 2, 2021 are as follows (in thousands): 2021 2022 Future minimum principal payments $ 28,125 664,473

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Apr. 02, 2021
Share-based Payment Arrangement [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended April 2, April 3, Stock options $ — $ 13 RSUs 4,704 1,725 Total stock-based compensation expense $ 4,704 $ 1,738 Cost of sales $ 1,114 $ 454 Selling, general and administrative 3,355 1,136 Research, development and engineering 235 148 Total stock-based compensation expense $ 4,704 $ 1,738
Schedule of Share-based Compensation, Stock Options Activity	The following table summarizes the Company’s stock option activity for the three month period ended April 2, 2021: Number of Weighted Weighted Aggregate Outstanding at December 31, 2020 281,873 $ 36.05 Exercised (4,229) 27.32 Outstanding and exercisable at April 2, 2021 277,644 $ 36.18 4.5 $ 15.4
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average fair value and assumptions used to value the TSR portion of the PRSUs granted are as follows: Three Months Ended April 2, April 3, Weighted average fair value $ 85.16 $ 107.42 Risk-free interest rate 0.19 % 1.53 % Expected volatility 41 % 30 % Expected life (in years) 3.0 2.9 Expected dividend yield — % — %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested RSU activity for the three month period ended April 2, 2021: Time-Vested Weighted Nonvested at December 31, 2020 207,923 $ 75.38 Granted 146,247 79.09 Vested (59,143) 63.94 Forfeited (2,327) 80.24 Nonvested at April 2, 2021 292,700 $ 79.51 The following table summarizes PRSU activity for the three month period ended April 2, 2021: Performance- Weighted Nonvested at December 31, 2020 219,391 $ 72.33 Granted 92,345 85.16 Vested (38,882) 37.75 Forfeited (65,941) 49.00 Nonvested at April 2, 2021 206,913 $ 91.98

Other Operating Expenses (Table

Other Operating Expenses (Tables)	3 Months Ended
	Apr. 02, 2021
Other Income and Expenses [Abstract]
Schedule of Other Operating Cost and Expense By Component	Other operating expenses comprise the following (in thousands): Three Months Ended April 2, April 3, Operational excellence initiatives $ 654 $ 974 Strategic reorganization and alignment — 548 Manufacturing alignment to support growth — 128 Acquisition and integration 84 356 Other general expenses 177 922 Total other operating expenses $ 915 $ 2,928
Schedule of Changes in Accrued Liabilities	The following table summarizes the change in accrued liabilities, presented within Accrued expenses and other current liabilities on the Condensed Consolidated Balance Sheets, related to the initiatives described above (in thousands): Operational December 31, 2020 $ 291 Charges incurred, net of reversals 654 Cash payments (306) April 2, 2021 $ 639

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Apr. 02, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability comprised the following (in thousands): December 31, 2020 $ 163 Additions to warranty reserve, net of reversals 15 Adjustments to pre-existing warranties (63) April 2, 2021 $ 115

Earnings Per Share (EPS) (Table

Earnings Per Share (EPS) (Tables)	3 Months Ended
	Apr. 02, 2021
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table sets forth a reconciliation of the information used in computing basic and diluted EPS (in thousands, except per share amounts): Three Months Ended April 2, April 3, Numerator for basic and diluted EPS: Net income $ 21,520 $ 31,100 Denominator for basic and diluted EPS: Weighted average shares outstanding - Basic 32,957 32,807 Dilutive effect of share-based awards 231 310 Weighted average shares outstanding - Diluted 33,188 33,117 Basic EPS $ 0.65 $ 0.95 Diluted EPS $ 0.65 $ 0.94
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): Three Months Ended April 2, April 3, Time-vested RSUs 10 101 PRSUs 64 24

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Apr. 02, 2021
Stockholders' Equity Note [Abstract]
Schedule of Common Stock Outstanding Roll Forward	The following is a summary of the number of shares of common stock issued, treasury stock and common stock outstanding for the three month periods ended April 2, 2021 and April 3, 2020: Issued Treasury Stock Outstanding Shares outstanding at December 31, 2020 32,908,178 — 32,908,178 Stock options exercised 4,229 — 4,229 Vesting of RSUs, net of shares withheld to cover taxes 62,295 — 62,295 Shares outstanding at April 2, 2021 32,974,702 — 32,974,702 Shares outstanding at December 31, 2019 32,847,017 (146,546) 32,700,471 Stock options exercised — 58,658 58,658 Vesting of RSUs, net of shares withheld to cover taxes — 66,876 66,876 Shares outstanding at April 3, 2020 32,847,017 (21,012) 32,826,005
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) (“AOCI”) comprises the following (in thousands): Defined Cash Foreign Total Tax Net-of-Tax December 31, 2020 $ (1,095) $ (4,956) $ 57,546 $ 51,495 $ 1,197 $ 52,692 Unrealized loss on cash flow hedges — (1,269) — (1,269) 266 (1,003) Realized gain on foreign currency hedges — (659) — (659) 139 (520) Realized loss on interest rate swap hedges — 1,034 — 1,034 (217) 817 Foreign currency translation loss — — (16,364) (16,364) — (16,364) April 2, 2021 $ (1,095) $ (5,850) $ 41,182 $ 34,237 $ 1,385 $ 35,622 December 31, 2019 $ (912) $ (2,358) $ 22,639 $ 19,369 $ 619 $ 19,988 Unrealized loss on cash flow hedges — (11,474) — (11,474) 2,410 (9,064) Realized gain on foreign currency hedges — (197) — (197) 41 (156) Realized loss on interest rate swap hedges — 748 — 748 (157) 591 Foreign currency translation loss — — (12,032) (12,032) — (12,032) April 3, 2020 $ (912) $ (13,281) $ 10,607 $ (3,586) $ 2,913 $ (673)

Financial Instruments and Fai_2

Financial Instruments and Fair Value Measurements (Tables)	3 Months Ended
	Apr. 02, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables provide information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Quoted Significant Significant April 2, 2021 Assets: Foreign currency contracts $ 28 $ — $ 28 $ — Liabilities: Foreign currency contracts 152 — 152 — Liabilities: Interest rate swap 5,726 — 5,726 — Liabilities: Contingent consideration 2,281 — — 2,281 December 31, 2020 Assets: Foreign currency contracts $ 2,070 $ — $ 2,070 $ — Liabilities: Interest rate swap 7,026 — 7,026 — Liabilities: Contingent consideration 3,900 — — 3,900 Information regarding the Company’s outstanding interest rate swap designated as cash flow hedges as of April 2, 2021 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 150,000 Jun 2020 Jun 2023 2.1785 % 0.1091 % $ (5,726) Other long-term liabilities Information regarding the Company’s outstanding interest rate swap designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Start Date End Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun 2020 Jun 2023 2.1785 % 0.1480 % $ (7,026) Other long-term liabilities Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 1,553 Apr 2021 Aug 2021 0.0232 UYU Peso $ 30 Prepaid expenses and other current assets 3,270 Apr 2021 Nov 2021 0.0227 UYU Peso 10 Prepaid expenses and other current assets 2,048 Jul 2021 Dec 2021 0.0228 UYU Peso (12) Prepaid expenses and other current assets 8,973 Apr 2021 Sep 2021 1.1949 Euro (133) Accrued expenses and other current liabilities 6,101 Apr 2021 Sep 2021 0.0454 MXN Peso 480 Accrued expenses and other current liabilities 7,269 Apr 2021 Dec 2021 0.0485 MXN Peso (1) Accrued expenses and other current liabilities 10,985 Apr 2021 Dec 2021 1.2206 Euro (362) Accrued expenses and other current liabilities 9,069 Apr 2021 Dec 2021 0.0490 MXN Peso (136) Accrued expenses and other current liabilities Information regarding outstanding foreign currency forward contracts designated as cash flow hedges as of December 31, 2020 is as follows (dollars in thousands): Notional Amount Start End $/Foreign Currency Fair Value Balance Sheet Location $ 16,132 Nov 2020 Sep 2021 1.1949 Euro $ 399 Prepaid expenses and other current assets 10,224 Jan 2021 Sep 2021 0.0454 MXN Peso 922 Prepaid expenses and other current assets 2,656 Jan 2021 Mar 2021 0.0443 MXN Peso 341 Prepaid expenses and other current assets 7,269 Apr 2021 Dec 2021 0.0485 MXN Peso 77 Prepaid expenses and other current assets 3,252 Jan 2021 Aug 2021 0.0232 UYU Peso 165 Prepaid expenses and other current assets 3,966 Jan 2021 Nov 2021 0.0227 UYU Peso 166 Prepaid expenses and other current assets
Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)	The following tables present the effect of cash flow hedge derivative instruments on other comprehensive income (loss) (“OCI”), AOCI and the Company’s Condensed Consolidated Statements of Operations for the three months ended April 2, 2021 and April 3, 2020 (in thousands): Three Months Ended April 2, 2021 April 3, 2020 Total Amount of Gain (Loss) on Cash Flow Hedge Activity Total Amount of Gain (Loss) on Cash Flow Hedge Activity Sales $ 290,467 $ 8 $ 328,426 $ (128) Cost of sales 205,981 624 231,724 325 Operating expenses 49,878 27 52,626 — Interest expense 8,532 (1,034) 10,361 (748) (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) Unrealized Gain (Loss) Recognized in OCI Realized Gain (Loss) Reclassified from AOCI Three months ended, Location in Statements of Operations and Comprehensive Income Three months ended, April 2, April 3, April 2, April 3, Interest rate swap $ 266 $ (6,387) Interest expense $ (1,034) $ (748) Foreign exchange forwards (886) (274) Sales 8 (128) Foreign exchange forwards (559) (4,813) Cost of sales 624 325 Foreign exchange forwards (90) — Operating expenses 27 —
Schedule of Estimated Fair Values for Contingent Consideration	The following table presents the changes in the estimated fair values of the Company’s liabilities for contingent consideration measured using significant unobservable inputs (Level 3) for the three months ended April 2, 2021 and April 3, 2020 (in thousands): Three Months Ended April 2, April 3, Fair value measurement at beginning of period $ 3,900 $ 4,200 Amount recorded for acquisitions — 2,700 Fair value measurement adjustment — (500) Payments (1) (1,621) — Foreign currency translation 2 — Fair value measurement at end of period $ 2,281 $ 6,400 __________ (1) Consists of payments associated with the Company’s acquisitions of InoMec and USB, resulting from achievement of revenue-based goals for the period from March 1, 2020 to February 28, 2021 for InoMec and January 1, 2020 to December 31, 2020 for USB.
Schedule of Contingent Consideration Measurement Inputs	The following table provides quantitative information associated with the fair value measurement of the Company’s liabilities for contingent consideration: April 2, 2021 Contingency Type Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 6,750 $ 2,281 Monte Carlo Revenue volatility 35.0 % Discount rate 4.0 % Projected year(s) of payment 2022-2024 December 31, 2020 Contingency Type Maximum Payout (undiscounted) Fair Value Valuation Technique Unobservable Inputs Weighted Average or Range Revenue-based payments $ 9,000 $ 3,900 Monte Carlo Revenue volatility 35.0 % Discount rate 4.0 % Projected year(s) of payment 2021-2024
Schedule of Equity Method Investments	Equity investments comprise the following (in thousands): April 2, December 31, Equity method investment $ 20,135 $ 21,470 Non-marketable equity securities 5,723 5,723 Total equity investments $ 25,858 $ 27,193 (13.) FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued) The components of (Gain) loss on equity investments for each period were as follows (in thousands): Three Months Ended April 2, April 3, Equity method investment (gain) loss $ 1,335 $ (1,925)

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Apr. 02, 2021
Segment Reconciliation [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table presents sales by product line (in thousands). Three Months Ended April 2, April 3, Segment sales by product line: Medical Cardio & Vascular $ 149,165 $ 179,205 Cardiac & Neuromodulation 108,408 107,820 Advanced Surgical, Orthopedics & Portable Medical 25,392 31,237 Total Medical 282,965 318,262 Non-Medical 7,502 10,164 Total sales $ 290,467 $ 328,426
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table presents income for the Company’s reportable segments (in thousands). Three Months Ended April 2, April 3, Segment income: Medical $ 55,525 $ 65,216 Non-Medical 2 1,213 Total segment income 55,527 66,429 Unallocated operating expenses (20,919) (22,353) Operating income 34,608 44,076 Unallocated expenses, net (9,630) (7,437) Income before taxes $ 24,978 $ 36,639

Revenue From Contracts With C_2

Revenue From Contracts With Customers (Tables)	3 Months Ended
	Apr. 02, 2021
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Major Customers by Reporting Segments	The following table presents revenues by significant customers, which are defined as any customer who individually represents 10% or more of a segment’s total revenues. Three Months Ended April 2, 2021 April 3, 2020 Customer Medical Non-Medical Medical Non-Medical Customer A 22% * 20% * Customer B 13% * 18% * Customer C 17% * 16% * Customer D * 26% * 19% All other customers 48% 74% 46% 81% __________ * Less than 10% of segment’s total revenues for the period.
Schedule of Revenue by Ship To Location	The following tables present revenues by significant ship to location, which is defined as any country where 10% or more of a segment’s total revenues are shipped. Three Months Ended April 2, 2021 April 3, 2020 Ship to Location Medical Non-Medical Medical Non-Medical United States 53% 69% 55% 44% Puerto Rico * * 12% * United Kingdom * 10% * 15% Singapore * * * 14% Canada * 11% * 12% All other countries 47% 10% 33% 15% __________ * Less than 10% of segment’s total revenues for the period.
Schedule of Contract with Customer, Asset and Liability	The opening and closing balances of the Company’s contract assets and contract liabilities are as follows (in thousands): April 2, December 31, Contract assets $ 44,686 $ 40,218 Contract liabilities 2,379 2,498

Business Acquisition (Acquisiti

Business Acquisition (Acquisition of Assets from InoMec Narrative) (Details) - USD ($) $ in Thousands	Feb. 19, 2020	Apr. 02, 2021	Dec. 31, 2020
Business Acquisition [Line Items]
Contingent consideration, range of outcomes, value, high		$ 6,750	$ 9,000
Goodwill		$ 852,243	$ 859,442
InoMec Ltd
Business Acquisition [Line Items]
Consideration transferred	$ 7,000
Payments to acquire business	5,300
Fair value of contingent consideration recognized	1,700
Contingent consideration, range of outcomes, value, high	$ 3,500
Contingent consideration payment period	4 years
Intangible assets acquired	$ 2,000
Goodwill	4,800
Property, plant and equipment acquired	300
Other working capital items acquired	$ 100
Acquired finite-lived intangible assets, weighted average useful life	5 years 10 months 24 days

Business Acquisition (Narrative

Business Acquisition (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Business Acquisition [Line Items]
Sales	$ 290,467	$ 328,426
InoMec Ltd
Business Acquisition [Line Items]
Sales	$ 800	400
InoMec Ltd | Other operating expenses
Business Acquisition [Line Items]
Acquisition related costs		$ 700

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Noncash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$ 2,981	$ 4,481
Purchase of intangible asset included in accrued expenses	0	1,000
Supplemental lease disclosures:
ROU assets obtained in exchange for new operating lease liabilities	$ 7,414	$ 7,427

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 70,552	$ 72,477
Work-in-process	64,320	58,806
Finished goods	18,943	18,040
Total	$ 153,815	$ 149,323

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets, Net (Schedule of Goodwill) (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2021USD ($)
Goodwill [Roll Forward]
Opening goodwill	$ 859,442
Foreign currency translation	(7,199)
Closing goodwill	852,243
Medical
Goodwill [Roll Forward]
Opening goodwill	842,442
Foreign currency translation	(7,199)
Closing goodwill	835,243
Non-Medical
Goodwill [Roll Forward]
Opening goodwill	17,000
Foreign currency translation	0
Closing goodwill	$ 17,000

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets, Net (Schedule of Definite-Lived and Indefinite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 975,807	$ 985,386
Accumulated amortization	(326,761)	(318,450)
Total estimated amortization expense	649,046	666,936
Trademarks And Tradenames
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets (excluding goodwill)	90,288	90,288
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	255,606	257,453
Accumulated amortization	(155,278)	(152,798)
Total estimated amortization expense	100,328	104,655
Customer lists
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	716,081	723,791
Accumulated amortization	(167,620)	(161,856)
Total estimated amortization expense	548,461	561,935
Other
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	4,120	4,142
Accumulated amortization	(3,863)	(3,796)
Total estimated amortization expense	$ 257	$ 346

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 10,450	$ 10,444
Cost of sales
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	3,268	3,269
Selling, general and administrative expenses
Finite-Lived Intangible Assets [Line Items]
Total intangible asset amortization expense	$ 7,182	$ 7,175

Goodwill and Other Intangible_6

Goodwill and Other Intangible Assets, Net (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) $ in Thousands	Apr. 02, 2021USD ($)
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2021	$ 30,835
2022	40,170
2023	38,751
2024	37,798
2025	36,483
After 2025	$ 465,009

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Unamortized discount on term loan B and debt issuance costs	$ (5,468)	$ (6,715)
Total debt	687,130	731,258
Current portion of long-term debt	(37,500)	(37,500)
Total long-term debt	649,630	693,758
Secured Debt | Loans Payable | Senior secured term loan A
Debt Instrument [Line Items]
Long-term debt, gross	220,312	229,687
Secured Debt | Loans Payable | Senior secured term loan B
Debt Instrument [Line Items]
Long-term debt, gross	$ 472,286	$ 508,286

Debt (Narrative) (Details)

Debt (Narrative) (Details)	3 Months Ended			13 Months Ended
	Oct. 01, 2021	Apr. 02, 2021USD ($)	Apr. 03, 2020USD ($)	Oct. 27, 2022	Dec. 31, 2020USD ($)
Loans Payable | Senior secured term loan A
Debt Instrument [Line Items]
Loss on extinguishment of debt			$ 300,000
Secured Debt | Revolving Credit Facility | Revolving line of credit
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity		$ 200,000,000
Outstanding borrowings		0
Line of credit facility, remaining borrowing capacity		$ 193,300,000
Secured Debt | Loans Payable | Senior secured term loan B
Debt Instrument [Line Items]
Debt instrument, discount, percentage		1.00%
Outstanding borrowings		$ 472,286,000			$ 508,286,000
Debt weighted average interest rate		3.50%
Debt prepayment		$ 36,000,000
Secured Debt | Loans Payable | Senior secured term loan B | Prime Rate
Debt Instrument [Line Items]
Variable rate basis spread		1.50%
Secured Debt | Loans Payable | Senior secured term loan B | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate basis spread		2.50%
Debt instrument, interest rate, floor		1.00%
Secured Debt | Loans Payable | Senior secured term loan A
Debt Instrument [Line Items]
Deferred amendment fee percentage		0.03125%
Total net leverage ratio		3
Outstanding borrowings		$ 220,312,000			$ 229,687,000
Debt weighted average interest rate		2.36%
Net leverage ratio incremental increase option		4.75
Debt instrument, covenant compliance, adjusted EBITDA to interest expense ratio		3
Secured Debt | Loans Payable | Senior secured term loan A | Forecast
Debt Instrument [Line Items]
Net leverage ratio incremental increase option	4.50			4
Secured Debt | Swingline Loans | Revolving line of credit
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity		$ 15,000,000
Secured Debt | Standby Letters of Credit | Revolving line of credit
Debt Instrument [Line Items]
Credit facility maximum borrowing capacity		$ 25,000,000
Secured Debt | Minimum | Revolving Credit Facility | Revolving line of credit
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage		0.175%
Secured Debt | Minimum | Loans Payable | Senior secured term loan A | Prime Rate
Debt Instrument [Line Items]
Variable rate basis spread		0.50%
Secured Debt | Minimum | Loans Payable | Senior secured term loan A | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate basis spread		1.50%
Secured Debt | Maximum | Revolving Credit Facility | Revolving line of credit
Debt Instrument [Line Items]
Line of credit facility, unused capacity, commitment fee percentage		0.25%
Secured Debt | Maximum | Loans Payable | Senior secured term loan A | Prime Rate
Debt Instrument [Line Items]
Variable rate basis spread		2.00%
Secured Debt | Maximum | Loans Payable | Senior secured term loan A | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Variable rate basis spread		3.00%
Standby Letters of Credit | Revolving Credit Facility | Revolving line of credit
Debt Instrument [Line Items]
Letters of credit outstanding, amount		$ 6,700,000

Debt (Long-term Debt Maturity S

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Apr. 02, 2021USD ($)
Debt Disclosure [Abstract]
2021	$ 28,125
2022	$ 664,473

Stock-Based Compensation (Alloc

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	$ 4,704	$ 1,738
Cost of sales
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	1,114	454
Selling, general and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	3,355	1,136
Research, development and engineering
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	235	148
Stock options
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	0	13
RSUs
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	$ 4,704	$ 1,725

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Options Activity) (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Apr. 02, 2021USD ($)$ / sharesshares
Stock Option Activity (in shares)
Options outstanding, beginning balance (in shares) | shares	281,873
Exercised (in shares) | shares	(4,229)
Options outstanding, ending balance (in shares) | shares	277,644
Options exercisable at period end (in shares) | shares	277,644
Weighted Average Exercise Price (in dollars per share)
Options outstanding, beginning (in dollars per share) | $ / shares	$ 36.05
Exercised (in dollars per share) | $ / shares	27.32
Options outstanding, ending (in dollars per share) | $ / shares	36.18
Options exercisable at period end (in dollars per share) | $ / shares	$ 36.18
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options outstanding, weighted average remaining contractual term	4 years 6 months
Options exercisable, weighted average remaining contractual term	4 years 6 months
Options outstanding, intrinsic value | $	$ 15.4
Options exercisable, intrinsic value | $	$ 15.4

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details)	3 Months Ended
	Apr. 02, 2021
Restricted Stock And Restricted Stock Units Time Based
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Requisite service period	3 years

Stock-Based Compensation (Valua

Stock-Based Compensation (Valuation Assumptions) (Details) - Performance-based RSUs (PSUs) - $ / shares	3 Months Ended		12 Months Ended
	Apr. 02, 2021	Apr. 03, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value (in dollars per share)	$ 85.16	$ 107.42
Risk-free interest rate	0.19%	1.53%
Expected volatility	41.00%	30.00%
Expected life (in years)	3 years	2 years 10 months 24 days
Expected dividend yield	0.00%	0.00%
Weighted average illiquidity discount	8.19%		8.00%

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)	3 Months Ended
	Apr. 02, 2021$ / sharesshares
Restricted Stock And Restricted Stock Units Time Based
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, beginning (in shares) | shares	207,923
Granted (in shares) | shares	146,247
Vested (in shares) | shares	(59,143)
Forfeited (in shares) | shares	(2,327)
Nonvested, ending (in shares) | shares	292,700
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, beginning (in dollars per share) | $ / shares	$ 75.38
Granted (in dollars per share) | $ / shares	79.09
Vested (in dollars per share) | $ / shares	63.94
Forfeited (in dollars per share) | $ / shares	80.24
Nonvested, ending (in dollars per share) | $ / shares	$ 79.51
Performance-based RSUs (PSUs)
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, beginning (in shares) | shares	219,391
Granted (in shares) | shares	92,345
Vested (in shares) | shares	(38,882)
Forfeited (in shares) | shares	(65,941)
Nonvested, ending (in shares) | shares	206,913
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, beginning (in dollars per share) | $ / shares	$ 72.33
Granted (in dollars per share) | $ / shares	85.16
Vested (in dollars per share) | $ / shares	37.75
Forfeited (in dollars per share) | $ / shares	49
Nonvested, ending (in dollars per share) | $ / shares	$ 91.98

Other Operating Expenses (Sched

Other Operating Expenses (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	$ 915	$ 2,928
Operational excellence initiatives
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	654	974
Strategic reorganization and alignment
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	0	548
Manufacturing alignment to support growth
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	0	128
Acquisition and integration
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	84	356
Other general expenses
Other Operating Income Expense Detail [Line Items]
Total other operating expenses	$ 177	$ 922

Other Operating Expenses (Narra

Other Operating Expenses (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Minimum
Restructuring Cost and Reserve [Line Items]
Expected costs	$ 1
Maximum
Restructuring Cost and Reserve [Line Items]
Expected costs	2
InoMec Ltd And US BioDesign LLC
Restructuring Cost and Reserve [Line Items]
Acquisition related costs	0.1	$ 0.9
US BioDesign LLC
Restructuring Cost and Reserve [Line Items]
Acquisition-related contingent consideration, fair value adjustment	0.5
Operational Excellence Initiatives, 2021 Initiatives
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	0.4
Operational Excellence Initiatives, 2020 Initiatives
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	3
Strategic Reorganization And Alignment
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	23
Manufacturing Alignment To Support Growth
Restructuring Cost and Reserve [Line Items]
Costs incurred since inception	$ 5.8

Other Operating Expenses (Sch_2

Other Operating Expenses (Schedule of Restructuring Reserve By Type of Cost) (Details) - Operational excellence initiatives $ in Thousands	3 Months Ended
	Apr. 02, 2021USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 291
Charges incurred, net of reversals	654
Cash payments	(306)
Ending balance	$ 639

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Effective income tax rate	13.80%	15.10%
Income (loss) before provision for income taxes	$ 24,978	$ 36,639
Discrete tax benefits	600	$ 1,000
Unrecognized tax benefits	5,500
Significant change in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit	3,400
Unrecognized tax benefits that would impact effective tax rate	5,500
Accrued payroll taxes	$ 9,700		$ 9,700

Commitments and Contingencies_2

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	3 Months Ended
	Apr. 02, 2021USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at beginning of period	$ 163
Additions to warranty reserve, net of reversals	15
Adjustments to pre-existing warranties	(63)
Balance at end of period	$ 115

Earnings Per Share (EPS) (Detai

Earnings Per Share (EPS) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Earnings Per Share [Abstract]
Net income	$ 21,520	$ 31,100
Denominator for basic and diluted EPS:
Weighted average shares outstanding, basic (in shares)	32,957	32,807
Dilutive effect of share-based awards (in shares)	231	310
Weighted average shares outstanding - Diluted (in shares)	33,188	33,117
Earnings per share:
Basic (in dollars per share)	$ 0.65	$ 0.95
Diluted (in dollars per share)	$ 0.65	$ 0.94
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested RSUs (in shares)	10	101
PRSUs (in shares)	64	24

Stockholders' Equity (Shares Is

Stockholders' Equity (Shares Issued and Outstanding) (Details) - shares	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Class Of Stock [Roll Forward]
Balance, beginning of period (in shares)	32,908,178
Shares outstanding beginning balance (in shares)	32,908,178	32,700,471
Stock options exercised (in shares)	4,229	58,658
Balance, end of period (in shares)	32,974,702
Shares outstanding ending balance (in shares)	32,974,702	32,826,005
Common Stock
Class Of Stock [Roll Forward]
Balance, beginning of period (in shares)	32,908,178	32,847,017
Stock options exercised (in shares)	4,229	0
Balance, end of period (in shares)	32,974,702	32,847,017
Treasury Stock, Common
Class Of Stock [Roll Forward]
Balance, beginning of period (in shares)	0	146,546
Stock options exercised (in shares)	0	58,658
Balance, end of period (in shares)	0	21,012
Restricted Stock
Class Of Stock [Roll Forward]
RSAs issued, net of forfeitures, and vesting of RSUs (in shares)	62,295	66,876
Restricted Stock | Common Stock
Class Of Stock [Roll Forward]
RSAs issued, net of forfeitures, and vesting of RSUs (in shares)	62,295	0
Restricted Stock | Treasury Stock, Common
Class Of Stock [Roll Forward]
RSAs issued, net of forfeitures, and vesting of RSUs (in shares)	0	66,876

Stockholders' Equity (Accumulat

Stockholders' Equity (Accumulated Other Comprehensive Income) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	$ 1,271,055	$ 1,152,488
Unrealized loss on cash flow hedges, net of tax	(1,003)	(9,064)
Foreign currency translation loss	(16,364)	(12,032)
Balance, ending balance	1,277,724	1,164,201
Foreign exchange contracts
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Realized gain (loss) hedges, net of tax	(520)	(156)
Interest rate swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Realized gain (loss) hedges, net of tax	817	591
Defined Benefit Plan Liability
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	(1,095)	(912)
Balance, ending balance	(1,095)	(912)
Cash Flow Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	(4,956)	(2,358)
Unrealized loss on cash flow hedges, pretax	(1,269)	(11,474)
Unrealized loss on cash flow hedges, tax	266	2,410
Balance, ending balance	(5,850)	(13,281)
Cash Flow Hedges | Foreign exchange contracts
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Realized gain (loss) hedges, pretax	(659)	(197)
Realized gain (loss) hedges, tax	139	41
Cash Flow Hedges | Interest rate swap
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Realized gain (loss) hedges, pretax	1,034	748
Realized gain (loss) hedges, tax	(217)	(157)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	57,546	22,639
Foreign currency translation loss, pretax	(16,364)	(12,032)
Foreign currency translation loss, tax	0	0
Balance, ending balance	41,182	10,607
Total Pre-Tax Amount
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	51,495	19,369
Balance, ending balance	34,237	(3,586)
Tax
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	1,197	619
Balance, ending balance	1,385	2,913
Net-of-Tax Amount
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, beginning of period	52,692	19,988
Balance, ending balance	$ 35,622	$ (673)

Financial Instruments and Fai_3

Financial Instruments and Fair Value Measurements (Assets and Liabilities Recorded at Fair Value on a Recurring Basis) (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	$ 28	$ 2,070
Liabilities: Foreign currency contracts	152
Liabilities: Interest rate swap	5,726	7,026
Liabilities: Contingent consideration	2,281	3,900
Quoted Prices in Active Markets (Level 1)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	0	0
Liabilities: Foreign currency contracts	0
Liabilities: Interest rate swap	0	0
Liabilities: Contingent consideration	0	0
Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	28	2,070
Liabilities: Foreign currency contracts	152
Liabilities: Interest rate swap	5,726	7,026
Liabilities: Contingent consideration	0	0
Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Assets: Foreign currency contracts	0	0
Liabilities: Foreign currency contracts	0
Liabilities: Interest rate swap	0	0
Liabilities: Contingent consideration	$ 2,281	$ 3,900

Financial Instruments and Fai_4

Financial Instruments and Fair Value Measurements (Schedule of Interest Rate Swaps) (Details) - Interest Rate Swap Maturing June 2023 - Other long-term liabilities - Designated as Hedging Instrument - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Derivatives, Fair Value [Line Items]
Notional Amount	$ 150,000	$ 200,000
Pay Fixed Rate	2.1785%	2.1785%
Receive Current Floating Rate	0.1091%	0.148%
Fair Value	$ (5,726)	$ (7,026)

Financial Instruments and Fai_5

Financial Instruments and Fair Value Measurements (Schedule of Foreign Currency Contracts) (Details) - Designated as Hedging Instrument $ in Thousands	Apr. 02, 2021USD ($)$ / €$ / $$ / $	Dec. 31, 2020USD ($)$ / $$ / $$ / €
Foreign Exchange Contract Maturing August 2021 | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount	$ 1,553	$ 3,252
$/Foreign currency (in dollars per foreign currency)	0.0232	0.0232
Fair Value	$ 30	$ 165
Foreign Exchange Contract Maturing November 2021 | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount	$ 3,270	$ 3,966
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0227	0.0227
Fair Value	$ 10	$ 166
Foreign Exchange Contract Maturing December 2021, Contract Two | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount	$ 2,048
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0228
Fair Value	$ (12)
Foreign Exchange Contract Maturing September 2021, Contract One | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount		$ 16,132
$/Foreign currency (in dollars per foreign currency) | $ / €		1.1949
Fair Value		$ 399
Foreign Exchange Contract Maturing September 2021, Contract One | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 8,973
$/Foreign currency (in dollars per foreign currency) | $ / €	1.1949
Fair Value	$ (133)
Foreign Exchange Contract Maturing September 2021, Contract Two | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount		$ 10,224
$/Foreign currency (in dollars per foreign currency) | $ / $		0.0454
Fair Value		$ 922
Foreign Exchange Contract Maturing September 2021, Contract Two | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 6,101
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0454
Fair Value	$ 480
Foreign Exchange Contract Maturing December 2021, Contract One | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount		$ 7,269
$/Foreign currency (in dollars per foreign currency) | $ / $		0.0485
Fair Value		$ 77
Foreign Exchange Contract Maturing December 2021, Contract One | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 7,269
$/Foreign currency (in dollars per foreign currency) | $ / €	0.0485
Fair Value	$ (1)
Foreign Exchange Contract Maturing December 2021, Contract Three | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 10,985
$/Foreign currency (in dollars per foreign currency) | $ / $	1.2206
Fair Value	$ (362)
Foreign Exchange Contract Maturing December 2021, Contract Four | Accrued expenses and other current liabilities
Derivatives, Fair Value [Line Items]
Notional Amount	$ 9,069
$/Foreign currency (in dollars per foreign currency) | $ / $	0.0490
Fair Value	$ (136)
Foreign Exchange Contract Maturing March 2021 | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Notional Amount		$ 2,656
$/Foreign currency (in dollars per foreign currency) | $ / $		0.0443
Fair Value		$ 341

Financial Instruments and Fai_6

Financial Instruments and Fair Value Measurements (Impact of Cash Flow Hedges on Other Comprehensive Income, AOCI and the Condensed Consolidated Statements of Operations) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Total sales	$ 290,467	$ 328,426
Cost of sales	205,981	231,724
Operating expenses	49,878	52,626
Interest expense	8,532	10,361
Sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	8	(128)
Sales | Foreign exchange forwards
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	(886)	(274)
Cost of sales
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	624	325
Cost of sales | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	(559)	(4,813)
Operating expenses
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	27	0
Operating expenses | Foreign exchange contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	(90)	0
Interest expense
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) reclassified from AOCI	(1,034)	(748)
Interest expense | Interest rate swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gain (loss) recognized in OCI	$ 266	$ (6,387)

Financial Instruments and Fai_7

Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2021	Dec. 31, 2020	Jul. 03, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative instruments net loss to be reclassified to net income during next twelve months	$ 3.2
Asset acquisition contingent consideration recognized			$ 1
Accrued expenses and other current liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration liability, current	1	$ 1.7
Other long-term liabilities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Contingent consideration liability, noncurrent	$ 1.3	$ 2.2
Chinese Venture Capital Fund
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equity method investment ownership (percent)	6.60%

Financial Instruments and Fai_8

Financial Instruments and Fair Value Measurements (Contingent Consideration Measurement Inputs) (Details) $ in Thousands	Apr. 02, 2021USD ($)	Dec. 31, 2020USD ($)
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 6,750	$ 9,000
Fair Value, Recurring
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Liabilities: Contingent consideration	$ 2,281	$ 3,900
Fair Value, Recurring | Revenue volatility | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	0.350	0.350
Fair Value, Recurring | Discount rate | Weighted Average
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Inputs	0.040	0.040

Financial Instruments and Fai_9

Financial Instruments and Fair Value Measurements (Estimated Fair Values for Contingent Consideration) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 3,900	$ 4,200
Amount recorded for acquisitions	0	2,700
Fair value measurement adjustment	0	(500)
Payments(1)	(1,621)	0
Foreign currency translation	2	0
Balance at end of period	$ 2,281	$ 6,400

Financial Instruments and Fa_10

Financial Instruments and Fair Value Measurements (Equity Method Investments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Equity method investment	$ 20,135		$ 21,470
Non-marketable equity securities	5,723		5,723
Total equity investments	25,858		$ 27,193
Equity method investment (gain) loss	$ 1,335	$ (1,925)

Segment Information (Narrative)

Segment Information (Narrative) (Details)	3 Months Ended
	Apr. 02, 2021segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information (Reconcilia

Segment Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 290,467	$ 328,426
Operating Segments | Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	282,965	318,262
Operating Segments | Medical | Cardio & Vascular
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	149,165	179,205
Operating Segments | Medical | Cardiac & Neuromodulation
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	108,408	107,820
Operating Segments | Medical | Advanced Surgical, Orthopedics & Portable Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	25,392	31,237
Operating Segments | Non-Medical
Segment Reporting, Revenue Reconciling Item [Line Items]
Total sales	$ 7,502	$ 10,164

Segment Information (Reconcil_2

Segment Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Segment Reporting Information [Line Items]
Operating income	$ 34,608	$ 44,076
Unallocated expenses, net	(9,630)	(7,437)
Income before taxes	24,978	36,639
Operating Segments
Segment Reporting Information [Line Items]
Operating income	55,527	66,429
Operating Segments | Medical
Segment Reporting Information [Line Items]
Operating income	55,525	65,216
Operating Segments | Non-Medical
Segment Reporting Information [Line Items]
Operating income	2	1,213
Segment Reconciling Items
Segment Reporting Information [Line Items]
Operating income	$ (20,919)	$ (22,353)

Revenue From Contracts With C_3

Revenue From Contracts With Customers (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Revenue from Contract with Customer [Abstract]
Percent of revenue from contract with customer compared to total revenue	35.00%	30.00%
Contract with customer, asset, cumulative catch-up adjustment to revenue, modification of contract	$ 4.5
Revenue recognized that was included in contract liability balance at beginning of period	$ 0.9	$ 0.1

Revenue From Contracts With C_4

Revenue From Contracts With Customers (Disaggregated Revenue) (Details) - Revenue from contract with customer benchmark - Customer Concentration Risk	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Medical | Customer A
Disaggregation of Revenue [Line Items]
Concentration risk percentage	22.00%	20.00%
Medical | Customer B
Disaggregation of Revenue [Line Items]
Concentration risk percentage	13.00%	18.00%
Medical | Customer C
Disaggregation of Revenue [Line Items]
Concentration risk percentage	17.00%	16.00%
Medical | All other customers
Disaggregation of Revenue [Line Items]
Concentration risk percentage	48.00%	46.00%
Non-Medical | Customer D
Disaggregation of Revenue [Line Items]
Concentration risk percentage	26.00%	19.00%
Non-Medical | All other customers
Disaggregation of Revenue [Line Items]
Concentration risk percentage	74.00%	81.00%

Revenue From Contracts With C_5

Revenue From Contracts With Customers (Schedule of Revenue by Ship To Location) (Details) - Geographic Concentration Risk - Revenue from contract with customer benchmark	3 Months Ended
	Apr. 02, 2021	Apr. 03, 2020
Medical Segment | United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	53.00%	55.00%
Medical Segment | Puerto Rico
Disaggregation of Revenue [Line Items]
Concentration risk percentage		12.00%
Medical Segment | All other countries
Disaggregation of Revenue [Line Items]
Concentration risk percentage	47.00%	33.00%
Non-Medical Segment | United States
Disaggregation of Revenue [Line Items]
Concentration risk percentage	69.00%	44.00%
Non-Medical Segment | Singapore
Disaggregation of Revenue [Line Items]
Concentration risk percentage		14.00%
Non-Medical Segment | United Kingdom
Disaggregation of Revenue [Line Items]
Concentration risk percentage	10.00%	15.00%
Non-Medical Segment | Canada
Disaggregation of Revenue [Line Items]
Concentration risk percentage	11.00%	12.00%
Non-Medical Segment | All other countries
Disaggregation of Revenue [Line Items]
Concentration risk percentage	10.00%	15.00%

Revenue From Contracts With C_6

Revenue From Contracts With Customers Contract with Customer (Assets and Liability) (Details) - USD ($) $ in Thousands	Apr. 02, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract assets	$ 44,686	$ 40,218
Contract liabilities	$ 2,379	$ 2,498